AR098024A1 - Fármaco para la prevención y/o tratamiento de la poliquistosis renal - Google Patents
Fármaco para la prevención y/o tratamiento de la poliquistosis renalInfo
- Publication number
- AR098024A1 AR098024A1 ARP140103821A ARP140103821A AR098024A1 AR 098024 A1 AR098024 A1 AR 098024A1 AR P140103821 A ARP140103821 A AR P140103821A AR P140103821 A ARP140103821 A AR P140103821A AR 098024 A1 AR098024 A1 AR 098024A1
- Authority
- AR
- Argentina
- Prior art keywords
- prevention
- treatment
- drug
- kidney disease
- polycystic kidney
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title abstract 5
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 3
- 230000002035 prolonged effect Effects 0.000 abstract 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 abstract 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 abstract 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 abstract 1
- 108010016076 Octreotide Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 108010021336 lanreotide Proteins 0.000 abstract 1
- 229960002437 lanreotide Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960002700 octreotide Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 abstract 1
- 108700017947 pasireotide Proteins 0.000 abstract 1
- 229960005415 pasireotide Drugs 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001256 tolvaptan Drugs 0.000 abstract 1
- 108700029852 vapreotide Proteins 0.000 abstract 1
- 229960002730 vapreotide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Un fármaco combinado para una formulación inyectable de liberación prolongada con un efecto superior para la prevención y/o tratamiento de la poliquistosis renal. En forma mas específica, un fármaco para la prevención y/o el tratamiento de la poliquistosis renal, que es una formulación inyectable de liberación prolongada que comprende una partícula que contiene tolvaptán o uno de sus profármacos y un análogo de somatostatina. Método para la prevención y/o tratamiento de la poliquistosis renal a través del uso del fármaco. Reivindicación 7: El fármaco para la prevención y/o el tratamiento de la poliquistosis renal de acuerdo con una cualquiera de las reivindicaciones 1 a 6, caracterizado porque el análogo de somatostatina es al menos un miembro seleccionado entre el grupo que consiste en somatostatina, octreótido, pasireótido, lanreótido, vapreótido, y sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013215137 | 2013-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098024A1 true AR098024A1 (es) | 2016-04-27 |
Family
ID=51904208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103821A AR098024A1 (es) | 2013-10-15 | 2014-10-15 | Fármaco para la prevención y/o tratamiento de la poliquistosis renal |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160250222A1 (es) |
| EP (1) | EP3057574A1 (es) |
| JP (1) | JP2016533317A (es) |
| AR (1) | AR098024A1 (es) |
| TW (1) | TW201605488A (es) |
| WO (1) | WO2015056805A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019003433A1 (ja) | 2017-06-30 | 2019-01-03 | 大塚製薬株式会社 | ベンゾアゼピン誘導体 |
| WO2019118272A1 (en) | 2017-12-11 | 2019-06-20 | Mayo Foundation For Medical Education And Research | Using probenecid to treat polycystic kidney disease |
| CN109528636B (zh) * | 2018-12-20 | 2022-05-03 | 常州市阳光药业有限公司 | 托伐普坦口服溶液及其制备方法 |
| CN113645954B (zh) * | 2019-03-28 | 2024-03-29 | 大塚制药株式会社 | 含有苯并氮杂卓化合物的冻干组合物 |
| KR20210144811A (ko) * | 2019-03-28 | 2021-11-30 | 오츠카 세이야쿠 가부시키가이샤 | 벤조아제핀 화합물-함유 제약 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH656884A5 (de) * | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| HU221294B1 (en) | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| DK0450097T3 (da) | 1989-10-20 | 1996-05-20 | Otsuka Pharma Co Ltd | Benzoheterocykliske forbindelser |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| JP4210355B2 (ja) | 1997-07-03 | 2009-01-14 | 大塚製薬株式会社 | 固形製剤組成物 |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| PL1968990T3 (pl) | 2005-12-27 | 2015-06-30 | Otsuka Pharma Co Ltd | Rozpuszczalny w wodzie związek benzoazepinowy i jego kompozycja farmaceutyczna |
| WO2008008650A1 (en) * | 2006-07-10 | 2008-01-17 | Indiana University Research And Technology Corporation | Methods for treating cystic kidney diseases |
| TWI405574B (zh) | 2007-06-21 | 2013-08-21 | Otsuka Pharma Co Ltd | 藥學固體製劑及其製造方法 |
| TWI459947B (zh) | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
| JP5590780B2 (ja) * | 2007-06-26 | 2014-09-17 | 大塚製薬株式会社 | 医薬 |
| PT2523653T (pt) | 2010-01-13 | 2018-06-28 | Ipsen Pharma Sas | Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina |
| TWI704919B (zh) * | 2012-05-31 | 2020-09-21 | 日商大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
| MX2015008220A (es) * | 2012-12-28 | 2015-09-29 | Otsuka Pharma Co Ltd | Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un proceso para producir la misma. |
-
2014
- 2014-10-13 TW TW103135349A patent/TW201605488A/zh unknown
- 2014-10-14 US US15/028,450 patent/US20160250222A1/en not_active Abandoned
- 2014-10-14 WO PCT/JP2014/077763 patent/WO2015056805A1/en not_active Ceased
- 2014-10-14 JP JP2016507943A patent/JP2016533317A/ja not_active Ceased
- 2014-10-14 EP EP14799560.9A patent/EP3057574A1/en not_active Withdrawn
- 2014-10-15 AR ARP140103821A patent/AR098024A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160250222A1 (en) | 2016-09-01 |
| TW201605488A (zh) | 2016-02-16 |
| JP2016533317A (ja) | 2016-10-27 |
| WO2015056805A1 (en) | 2015-04-23 |
| EP3057574A1 (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| MX2015000990A (es) | Analogos del glucagon. | |
| MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
| CO2017005995A2 (es) | Composiciones para el cuidado bucal y métodos de uso | |
| EP3368089C0 (en) | NANOPARTICLE FORMULATIONS FOR THE ADMINISTRATION OF NUCLEIC ACID COMPLEXES | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| CR20170129A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2016001405A1 (es) | A peptide mixture | |
| AR102869A1 (es) | Composiciones de insulina de rápida acción | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| SV2017005515A (es) | Formulaciones de polvo nasal para el tratamiento de la hipoglicemia | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| AR102203A1 (es) | Composiciones para el cuidado oral que comprenden zinc, arginina y serina | |
| PL3226854T3 (pl) | Kompozycja na bazie aminokwasów do odbudowy fibroelastyny w tkance łącznej skóry | |
| AR091205A1 (es) | Farmaco para prevenir y tratar la enfermedad renal poliquistica | |
| AR098024A1 (es) | Fármaco para la prevención y/o tratamiento de la poliquistosis renal | |
| CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
| CL2016001210A1 (es) | Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. | |
| UY34776A (es) | Formulaciones de bromocriptina | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| ECSP16058769A (es) | Composicion para la administracion oral de agente bioactivos | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |